Ocrevus Side Effects: What They Are and How to Manage Them

What Is Ocrevus?

Ocrevus is the brand name for ocrelizumab, a monoclonal antibody that targets CD20-positive B cells. These immune cells contribute to the inflammatory damage associated with multiple sclerosis, or MS. By reducing selected B-cell populations, Ocrevus can decrease inflammatory disease activity, but the same immune effect can also make certain infections easier to develop.

Ocrevus is administered through an intravenous infusion. After the initial two-part dose, most adult patients receive one infusion approximately every six months. In the United States, it is approved for relapsing forms of MS and primary progressive MS in adults. It is also approved for relapsing-remitting MS in children ages 10 and older who weigh at least 55 pounds, or 25 kilograms.

This article focuses on intravenous Ocrevus. Ocrevus Zunovo contains ocrelizumab with hyaluronidase and is administered as a subcutaneous injection. The two products share several safety concerns, but their administration-related reactions are not identical.

What Are the Most Common Ocrevus Side Effects?

Infusion Reactions

Infusion reactions are among the most frequently reported Ocrevus side effects. In adult clinical trials, they occurred in about 34% of patients with relapsing forms of MS and 40% of patients with primary progressive MS. In the pediatric relapsing-remitting MS trial, infusion reactions occurred in 48% of Ocrevus-treated patients. The first infusion generally carries the greatest likelihood of a reaction, and the frequency often decreases with later doses.

Possible symptoms include:

• Itching, rash, hives, or facial flushing
• Headache, dizziness, fever, or fatigue
• Nausea or a racing heartbeat
• Coughing, wheezing, or throat irritation
• Shortness of breath or swelling in the throat
• Feeling faint or unusually weak

These reactions may begin while the medication is being administered or develop within 24 hours after the infusion. Most are mild or moderate, but serious reactions can occur.

Upper Respiratory Tract Infections

Colds, sore throats, sinus symptoms, and similar upper respiratory infections are also common. In adult relapsing-MS trials, upper respiratory tract infections occurred in 40% of Ocrevus-treated patients compared with 33% of patients receiving interferon beta-1a. In the primary progressive MS trial, the rates were 49% with Ocrevus and 43% with placebo.

Many infections were mild or moderate, but that does not mean every persistent cough deserves to be treated like an annoying background character. Contact your healthcare team when symptoms are severe, worsening, unusually long-lasting, or accompanied by breathing difficulty, chest pain, dehydration, or a high fever.

Lower Respiratory and Skin Infections

Bronchitis and other lower respiratory infections can occur, along with bacterial or fungal skin infections. Watch for increasing redness, warmth, swelling, pain, drainage, or a wound that refuses to heal. Your healthcare provider may postpone an upcoming infusion until an active infection has resolved.

Herpes-Related Infections

Ocrevus may increase the likelihood of cold sores, genital herpes, or shingles. Most herpes infections reported in controlled trials were mild or moderate. Rare, serious herpes infections involving the brain, eyes, or widespread areas of the body have been reported after approval.

Seek prompt medical guidance for a painful blistering rash, new eye pain or redness, vision changes, confusion, a stiff neck, or a severe persistent headache.

Other Reported Effects

Depending on the type of MS and the study population, other reported effects have included cough, diarrhea, back pain, swelling in the extremities, depression, and pain in an arm or leg. Some symptoms may also come from MS itself, another medication, an infection, or an infusion premedication, so timing and context matter.

Serious Ocrevus Side Effects and Warning Signs

Serious Infections

Because Ocrevus affects B cells, it can weaken part of the immune response. Serious bacterial, viral, fungal, and opportunistic infections are possible during treatment and may occur after the most recent dose. Call your healthcare provider promptly for fever, chills, persistent coughing, painful urination, worsening weakness, or other suspected infection symptoms.

Get emergency care for severe breathing difficulty, blue or gray lips, confusion, fainting, severe dehydration, or other rapidly worsening symptoms.

Hepatitis B Reactivation

Ocrevus can reactivate hepatitis B virus in someone who has a current or previous infection. Reactivation can lead to serious liver damage, liver failure, or death. Patients should be screened for hepatitis B before treatment begins. People with active hepatitis B infection should not receive Ocrevus.

A patient with evidence of an old infection or carrier status may need consultation with a liver specialist and ongoing monitoring during and after treatment.

Progressive Multifocal Leukoencephalopathy

Progressive multifocal leukoencephalopathy, usually shortened to PML, is a rare but potentially fatal brain infection. It may cause disability even when it is recognized and treated quickly.

Contact your medical team immediately for neurologic changes that are new, worsening, and lasting several days. Warning signs may include:

• New weakness affecting one side of the body
• Changes in eyesight
• Difficulty thinking, speaking, or using the limbs
• Loss of balance or coordination
• Unusual personality or behavioral changes

These symptoms can resemble an MS relapse, which is precisely why they should be medically evaluated rather than diagnosed at home.

Reduced Immunoglobulin Levels

Immunoglobulins are antibodies that help defend the body against infection. Ocrevus may gradually reduce certain immunoglobulin levels, especially IgM. Reduced IgG has been associated with a higher rate of serious infections during long-term exposure.

Your clinician may check quantitative immunoglobulin levels before treatment and periodically afterward. Recurrent pneumonia, frequent sinus infections, or other repeated infections may lead the care team to reconsider the treatment schedule, seek an immunology consultation, or discuss other options.

Immune-Mediated Colitis

Inflammation of the colon has been reported in people receiving Ocrevus. Some cases required hospitalization, corticosteroid treatment, or surgery. Symptoms may appear weeks or years after treatment begins.

Contact your clinician for new or persistent diarrhea, severe abdominal pain, unusual bowel frequency, or stools containing blood or mucus. Black, tarry stools or intense abdominal pain require urgent assessment.

Liver Injury

Clinically significant liver injury has occurred with Ocrevus and other B-cell-depleting therapies. Liver tests should be obtained before treatment, with additional testing when medically indicated.

Report yellowing of the skin or eyes, dark urine, unusual fatigue, loss of appetite, persistent nausea, vomiting, or pain in the upper-right abdomen. These symptoms are not a situation for the “maybe it will disappear after the weekend” strategy.

Possible Malignancy Risk

The prescribing information states that an increased risk of malignancy, including breast cancer, may exist. This warning does not prove that Ocrevus will cause cancer in an individual patient. Patients should follow standard, age-appropriate cancer screening recommendations and discuss personal or family risk factors with their healthcare providers.

How to Manage Ocrevus Side Effects

Before Starting Treatment

Before the first dose, the care team generally reviews infection history, medications, immune-system treatments, vaccination status, liver health, bowel disease, pregnancy plans, hepatitis B test results, immunoglobulin levels, and liver-function tests.

Age-appropriate live or live-attenuated vaccines should generally be completed at least four weeks before starting Ocrevus. When possible, non-live vaccines should be given at least two weeks before treatment. Live vaccines are not recommended during therapy or after discontinuation until the treating clinician confirms adequate B-cell recovery.

Vaccines administered during B-cell-depleting treatment may produce a weaker antibody response. Your neurologist or primary-care clinician can help coordinate influenza, COVID-19, shingles, pneumococcal, and other recommended vaccines around the infusion schedule.

Before Each Infusion

Tell the infusion center about fever, respiratory symptoms, painful urination, an open wound, a new rash, recent antibiotic use, or any diagnosed infection. The infusion may be delayed while an active infection resolves.

Patients usually receive a corticosteroid and an antihistamine before Ocrevus to reduce the frequency and severity of infusion reactions. Acetaminophen or another fever-reducing medication may also be considered by the treatment team. Do not add extra medications on your own simply because an internet checklist told you to arrive carrying half a pharmacy.

During the Infusion

Report itching, flushing, throat discomfort, chest tightness, nausea, dizziness, breathing changes, or any sudden symptom immediately. Do not wait until it becomes dramatic enough for its own soundtrack.

For a mild or moderate reaction, the nurse may slow the infusion and provide additional medication. A severe reaction may require interrupting treatment until symptoms resolve. A life-threatening or disabling infusion reaction generally requires permanent discontinuation and emergency treatment.

After the Infusion

Patients are monitored for at least one hour after an Ocrevus infusion. Because reactions can occur later, continue watching for symptoms during the next 24 hours. Keep the infusion center’s after-hours number available, and make sure you understand when the center wants you to call versus when you should seek emergency care.

Some premedications can cause drowsiness, while corticosteroids may cause temporary restlessness, appetite changes, flushing, or difficulty sleeping. Arrange transportation when your clinic recommends it, particularly when you do not know how you will respond to the antihistamine.

Between Infusions

Good infection prevention is useful without turning daily life into a low-budget quarantine movie. Wash your hands regularly, avoid close contact with people who are actively ill when practical, care for wounds promptly, keep recommended non-live vaccines current, and report repeated infections.

Maintain a simple symptom record containing the date, severity, duration, possible triggers, treatment used, and whether the symptom occurred during an infusion, within 24 hours, or weeks later. A clear timeline can help distinguish an infusion reaction from an infection, MS symptom, or unrelated medical problem.

When Should You Call a Doctor?

Contact your healthcare provider promptly for:

• Fever, chills, persistent coughing, or painful urination
• A painful blistering rash or suspected shingles
• Persistent diarrhea, bloody stools, or worsening abdominal pain
• Dark urine, jaundice, unexplained vomiting, or loss of appetite
• Repeated infections or infections that are becoming harder to clear
• New neurologic symptoms lasting several days

Call 911 or seek emergency medical care for severe shortness of breath, throat or facial swelling, fainting, chest tightness, rapidly spreading hives, confusion, or another potentially life-threatening reaction.

Do Ocrevus Side Effects Improve Over Time?

Infusion reactions frequently become less common with subsequent treatments, although a reaction can still occur after a previously uneventful dose. Infection risk and immunoglobulin changes require longer-term monitoring because immune effects continue between infusions.

Do not assume that every new symptom is caused by Ocrevus. MS, seasonal viruses, sleep loss, stress, other medications, and unrelated health conditions can all join the party without being invited. Your medical team can evaluate the timing, examination findings, laboratory results, and treatment history before deciding whether Ocrevus is responsible.

Questions to Ask Your Neurologist

• Which laboratory tests will be checked before and during treatment?
• How should my vaccinations be timed around each infusion?
• Which infection symptoms should trigger an immediate call?
• What should I do if I develop diarrhea, shingles, or liver-related symptoms?
• How often will my immunoglobulin levels be monitored?
• Could another medication increase my infection or infusion-reaction risk?
• Who should I contact if symptoms appear after the infusion center closes?

What the Ocrevus Treatment Experience Can Feel Like

The following is an illustrative composite based on commonly described treatment experiences. It is not a testimonial from one identifiable patient and does not predict how any individual will respond.

For many people, the first Ocrevus appointment feels like a cross between a medical procedure and a very long airport layover. There is paperwork, a comfortable chair if fortune smiles upon you, an IV line, vital-sign checks, premedications, and enough waiting time to reconsider every entertainment choice on your phone.

The antihistamine may make a patient sleepy before the Ocrevus infusion even begins. The corticosteroid can produce the opposite effect: alertness, warmth, a metallic taste, or the temporary confidence that reorganizing the entire garage at midnight is an excellent plan. Experiences vary, and some people notice almost nothing from the premedications.

During the infusion, a patient may develop mild itching, flushing, a headache, or a scratchy sensation in the throat. The most important response is not panic and not silence. It is simply telling the nurse. The infusion team may slow the rate, pause treatment, check vital signs, or provide another medication. A slower infusion does not mean treatment has failed. It means the safety plan is doing its job.

Afterward, some patients feel tired and plan a quiet evening. Others feel relatively normal. A few experience headache, nausea, poor sleep, or a “washed out” feeling for a day or two. Because symptoms can also come from the steroid, antihistamine, dehydration, disrupted sleep, or MS fatigue, it helps to record what occurred and how long it lasted rather than immediately blaming the infusion for every bodily complaint.

The second half of the initial dose, usually administered two weeks later, may feel more predictable because the patient now knows the building, the routine, and which snack does not crumble into the infusion-chair upholstery. Many people report fewer or milder infusion reactions with later doses, although continued monitoring remains necessary.

Life between infusions often becomes less centered on treatment. Instead of thinking about medication every day, a patient may mainly focus on laboratory appointments, infection precautions, and the next six-month date. That convenience can be meaningful, but it does not eliminate the need to watch for persistent respiratory infections, urinary symptoms, shingles, or repeated illnesses.

Some people become anxious whenever they develop a cough or unusual fatigue. A written action plan can reduce uncertainty: mild symptoms are monitored, concerning symptoms prompt a call, and severe breathing or neurologic problems require emergency evaluation. Having those instructions before a problem appears is far more useful than trying to interpret five browser tabs while running a fever.

Patients may also hear the informal phrase “crap gap,” used by some people with MS to describe increased fatigue or familiar symptoms before the next infusion. This experience is not universal, and it does not automatically indicate that Ocrevus has stopped working or that new MS activity is occurring. New, severe, or persistent symptoms still deserve evaluation rather than an improvised change to the infusion schedule.

Over time, many patients develop a personal routine: completing bloodwork early, confirming vaccines with the neurologist, wearing comfortable clothes, bringing a charger, preparing an easy dinner, and leaving the following morning flexible. None of these steps prevents every side effect, but they can make treatment days less disruptive.

The central lesson from real-world treatment experience is that good communication matters. Reporting symptoms early gives the infusion team more options. Tracking infections helps the neurologist recognize patterns. Asking questions about vaccines, laboratory results, and screening turns the patient into an informed member of the treatment teamnot an anxious passenger wondering who is steering.

Conclusion

The most common Ocrevus side effects are infusion reactions and respiratory infections. Most infusion reactions can be managed through premedication, close monitoring, slower infusion rates, or temporary interruption. More serious concerns include severe infections, hepatitis B reactivation, PML, reduced immunoglobulins, immune-mediated colitis, liver injury, and a possible increased malignancy risk.

Managing Ocrevus safely depends on preparation and communication: complete recommended screening, coordinate vaccinations, report infections before an infusion, speak up immediately about infusion symptoms, and know which warning signs require urgent care. Ocrevus may be given only twice a year, but safety monitoring is a year-round partnership.